PGEN
Precigen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Net Income Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PGEN
Precigen, Inc.
A clinical-stage biopharmaceutical company that develops gene and cell therapies for urgent and intractable diseases
20374 Seneca Meadows Parkway, Germantown, Maryland
--
Precigen, Inc., an Ohio limited liability company, was founded. The company was re-registered as a Virginia corporation in 2004. Precigen, Inc., is a leader in synthetic biology, an emerging and rapidly growing discipline that applies engineering principles to biological systems. The company utilizes its suite of proprietary and complementary technologies to design, construct and regulate genetic programs, which are DNA sequences composed of key genetic components.
Company Financials
EPS
PGEN has released its 2025 Q3 earnings. EPS was reported at -1.06, versus the expected -0.09, missing expectations. The chart below visualizes how PGEN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PGEN has released its 2025 Q3 earnings report, with revenue of 2.92M, reflecting a YoY change of 206.61%, and net profit of -146.34M, showing a YoY change of -510.33%. The Sankey diagram below clearly presents PGEN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
